The Transdermal Drug Delivery System Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the transdermal drug delivery system market are listed below:Starton Therapeutics Inc. has filed provisional patent applications with the U.S. Patent and Trademark Office (USPTO) for unique and novel approaches to incorporate various active pharmaceutical ingredients (APIs) into transdermal drug delivery systems, where such APIs have typically been difficult to incorporate in a transdermal drug delivery system platform. (Source: Starton Therapeutics, Company Website, January 2024)Satio has received a $3.5 million Small Business Innovation Research (SBIR) contract from Advanced Research Projects Agency for Health (ARPA-H), National Institutes of Health, Department of Health and Human Services. This SatioRx device is designed to be compact and inexpensive, with disposable microneedle components that allow healthcare providers to remotely deliver a precise metered dose of any liquid drug approved for transdermal delivery by the FDA. Under this contract, Satio will leverage design features from its other patch-based devices and feasibility data from its manually operated transdermal delivery devices to develop the next-generation remotely controllable device. (Source: Satio, Company Website, September 2023)
source:https://www.theinsightpartners.com/
https://www.theinsightpartners.com/assets/images/other/report-deliverables-img1.webp
